We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Membrane Shedding During Septic Shock

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01604551
Recruitment Status : Completed
First Posted : May 23, 2012
Last Update Posted : June 1, 2012
Information provided by (Responsible Party):
University Hospital, Strasbourg, France

Brief Summary:
Microparticles (MPs) result from plasma cell membrane remodeling and shedding after cell stimulation or apoptosis. MPs are know recognized as a pool of bioactive messengers with emerging role in pathophysiology of immune and cardiovascular diseases. MPs have been characterized during septic shock and may contribute to dissemination of pro-inflammatory and procoagulant mediators. This is a prospective observational study of circulating MPs and blood coagulation in 100 septic shock patients admitted in 3 tertiary hospitals medical ICU at baseline (D1), D2, D3, D4 and D7.

Condition or disease
Septic Shock

Study Type : Observational
Actual Enrollment : 100 participants
Time Perspective: Prospective
Official Title: Membrane Shedding During Severe Sepsis and Septic Shock: Pathophysiological and Clinical Relevance
Study Start Date : May 2003
Study Completion Date : December 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Shock
U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with septic shock

Inclusion Criteria:

  • Septic shock
  • Informed consent

Exclusion Criteria:

  • Class IV heart failure
  • Child-Plugh grade C cirrhosis
  • Cancer under active treatment
  • BMI>35 kg/m²
  • Moribund patient
  • DNR decision

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01604551

Service Réanimation Médicale et Médecine Hyperbare, CHU
Angers, France, 49933
Centre Hospitalier
Mulhouse, France, 68070
Service de Réanimation Médicale, Nouvel Hôpital Civil, Hôpitaux Universitaires
Strasbourg, France, 67091
Sponsors and Collaborators
University Hospital, Strasbourg, France
Principal Investigator: Xavier DELABRANCHE, MD Service de Réanimation Médicale, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, France

Responsible Party: University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier: NCT01604551     History of Changes
Other Study ID Numbers: 4649
First Posted: May 23, 2012    Key Record Dates
Last Update Posted: June 1, 2012
Last Verified: May 2012

Additional relevant MeSH terms:
Shock, Septic
Pathologic Processes
Systemic Inflammatory Response Syndrome